Glenmark Life Sciences vs Glenmark Pharmaceuticals Which Offers More Value?

Glenmark Life Sciences and Glenmark Pharmaceuticals are both entities under the umbrella of the Glenmark Group, a leading pharmaceutical company based in India. While Glenmark Pharmaceuticals focuses on the development and marketing of branded and generic pharmaceutical products, Glenmark Life Sciences primarily specializes in the manufacture of active pharmaceutical ingredients (APIs) and intermediates. Investors interested in the pharmaceutical sector may find opportunities in both stocks, with each offering different potential for growth and returns.

Glenmark Life Sciences or Glenmark Pharmaceuticals?

When comparing Glenmark Life Sciences and Glenmark Pharmaceuticals, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Glenmark Life Sciences and Glenmark Pharmaceuticals.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Glenmark Life Sciences has a dividend yield of -%, while Glenmark Pharmaceuticals has a dividend yield of 0.16%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Glenmark Life Sciences reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Glenmark Pharmaceuticals reports a 5-year dividend growth of 4.56% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Glenmark Life Sciences P/E ratio at 29.45 and Glenmark Pharmaceuticals's P/E ratio at -48.96. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Glenmark Life Sciences P/B ratio is 4.91 while Glenmark Pharmaceuticals's P/B ratio is 5.07.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Glenmark Life Sciences has seen a 5-year revenue growth of 0.62%, while Glenmark Pharmaceuticals's is 0.22%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Glenmark Life Sciences's ROE at 17.66% and Glenmark Pharmaceuticals's ROE at -10.33%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are ₹1004.40 for Glenmark Life Sciences and ₹1446.50 for Glenmark Pharmaceuticals. Over the past year, Glenmark Life Sciences's prices ranged from ₹627.15 to ₹1335.10, with a yearly change of 112.88%. Glenmark Pharmaceuticals's prices fluctuated between ₹771.00 and ₹1830.95, with a yearly change of 137.48%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.